Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5270-5277

  Kaumaya, Pravin T P ^a   Foy, Kevin Chu ^a   Garrett, Joan ^a   Rawale, Sharad V ^a   Vicari, Daniele ^a   Thurmond, Jennifer M ^a   Lamb, Tammy ^a   Mani, Aruna ^a   Kane, Yahaira ^a   Balint, Catherine R ^a   Chalupa, Donald ^a   Otterson, Gregory A ^a   Shapiro, Charles L ^a   Fowler, Jeffrey M ^a   Grever, Michael R ^a   Bekaii Saab, Tanios S ^a   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MURAMYL DIPEPTIDE; MVF 316; MVF 339; MVF 628; MVF 647; UNCLASSIFIED DRUG; EPITOPE; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; COMPUTER ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOGENICITY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; OVARY CANCER; OVARY CARCINOMA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; BLOOD; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 70449727895     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3883     Document Type: Article

References (35)

1. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987
3. Hudziak RM, Lewis GD, Winget M, et al: P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989
4. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
5. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
6. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
8. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
9. Nahta R, Hung MC, Esteva FJ: The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343-2346, 2004
10. Weber J: Peptide vaccines for cancer. Cancer Invest 20:208-221, 2002
11. Buteau C, Markovic SN, Celis E: Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 77:339-349, 2002
12. Lazoura E, Apostolopoulos V: Rational Peptidebased vaccine design for cancer immunotherapeutic applications. Curr Med Chem 12:629-639, 2005
13. Disis ML, Pupa SM, Gralow JR, et al: Hightiter HER2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363-3367, 1997
14. Ioannides CG, Fisk B, Fan D, et al: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu protooncogene. Cell Immunol 151:225-234, 1993
15. Yoshino I, Goedegebuure PS, Peoples GE, et al: HER2/neu-derived peptides are shared antigens among human non-small-cell lung cancer and ovarian cancer. Cancer Res 54:3387-3390, 1994
16. Disis ML, Calenoff E, McLaughlin G, et al: Existent T-cell and antibody immunity to HER2/neu protein in patients with breast cancer. Cancer Res 54:16-20, 1994
17. Disis ML, Gralow JR, Bernhard H, et al: Peptide-based, but not whole protein, vaccines elicit immunity to HER2/neu, oncogenic self-protein. J Immunol 156:3151-3158, 1996
18. Disis ML, Grabstein KH, Sleath PR, et al: Generation of immunity to the HER2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5:1289-1297, 1999
19. Peoples GE, Gurney JM, Hueman MT, et al: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536-7545, 2005
20. Knutson KL, Schiffman K, Disis ML: Immunization with a HER2/neu helper peptide vaccine generates HER2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477-484, 2001
21. Dakappagari NK, Douglas DB, Triozzi PL, et al: Prevention of mammary tumors with a chimeric HER2 B-cell epitope peptide vaccine. Cancer Res 60:3782-3789, 2000
22. Dakappagari NK, Pyles J, Parihar R, et al: A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 170:4242-4253, 2003
23. Allen SD, Garrett JT, Rawale SV, et al: Peptide vaccines of the HER2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 179:472-482, 2007
24. Garrett JT, Rawale S, Allen SD, et al: Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER2/neu. J Immunol 178:7120-7131, 2007
25. Fisk B, Blevins TL, Wharton JT, et al: Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117, 1995
26. Disis ML, Gooley TA, Rinn K, et al: Generation of T-cell immunity to the HER2/neu protein after active immunization with HER2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632, 2002
27. Nanni P, Landuzzi L, Nicoletti G, et al: Immunoprevention of mammary carcinoma in HER2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 173:2288-2296, 2004
28. Park JM, Terabe M, Sakai Y, et al: Early role of CD4+ Th1 cells and antibodies in HER2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 174:4228-4236, 2005
29. Quaglino E, Rolla S, Iezzi M, et al: Concordant morphologic and gene expression data show that a vaccine halts HER2/neu preneoplastic lesions. J Clin Invest 113:709-717, 2004
30. Quaglino E, Iezzi M, Mastini C, et al: Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER2/neu transgenic mice. Cancer Res 64:2858-2864, 2004
31. Montgomery RB, Makary E, Schiffman K, et al: Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650-656, 2005
32. Partidos CD, Steward MW: Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J Gen Virol 71:2099-2105, 1990
33. Baxevanis CN, Sotiriadou NN, Gritzapis AD, et al: Immunogenic HER2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55:85-95, 2006
34. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760, 2003
35. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004